TIFA Protein Expression is Associated with Pulmonary Arterial Hypertension

Hao-Chih Chang
Taipei Veterans General Hospital

Tong-You Wade Wei
Academia Sinica

Pei-Yu Wu
Academia Sinica

Ming-Daw Tsai
Academia Sinica

Wen-Chung Yu
Taipei Veterans General Hospital

Chen-Huan Chen
National Yang Ming University

Shih-Hsien Sung (✉ mr.sungsh@gmail.com)
Taipei Veterans General Hospital

Research Article

Abstract

Tumor necrosis factor receptor-associated factor-interacting protein with a forkhead-associated domain (TIFA), a key regulator of inflammation, may be involved in the pathogenesis of pulmonary arterial hypertension (PAH). A total of 48 PAH patients (age 50.1±13.1 years, 22.9% men), 25 hypertensive subjects, and 26 healthy controls were enrolled. TIFA protein expression in peripheral blood mononuclear cells (PBMCs) and plasma interleukin (IL)-1β and tumor necrosis factor (TNF)-α were measured. Pulmonary arterial hemodynamics were derived from right heart catheterization. PAH patients had the highest expression of TIFA, TNF-α, and IL-1β. TIFA protein expression was significantly associated with IL-1β (r=0.94; P<0.001), TNF-α (r=0.93; P<0.001), mean pulmonary artery pressure (r=0.41; P=0.006), and pulmonary vascular resistance (r=0.41; P=0.007). TIFA protein expression could independently predict the presence of PAH (odds ratio [95% confidence interval per-0.1 standard deviation]: 1.72 [1.37-2.16]; P<0.001) and outperformed echocardiographic estimation. *Ex vivo* silencing of TIFA protein expression in PBMCs led to the suppression of the cellular expression of IL-1β and TNF-α. IL-1β and TNF-α mediated 80.4% and 56.6% of the causal relationship between TIFA and PAH, respectively, supporting the idea that TIFA protein is involved in the pathogenesis of PAH.

Introduction

Pulmonary arterial hypertension (PAH), classified as group 1 pulmonary hypertension by the World Health Organization (WHO), causes a devastating decline in the cardiac function and is associated with poor prognosis if untreated. Although great advancements have been achieved in early diagnosis and pharmacological therapies in the past two decades, the 5-year survival rate (57%) remains low.[1, 2] The pathobiology of PAH involves the remodeling of the pulmonary vasculature that includes vasoconstriction and smooth muscle cell proliferation.[3] Accumulating evidence suggests the pathogenic role of inflammation in mediating deteriorated vascular remodeling in PAH.[4, 5] Soon *et al.* demonstrated significantly higher levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 in 58 patients with idiopathic PAH than in healthy controls.[6, 7] Higher serum levels of TNF-α, IL-1β, and IL-6 were associated with worse pulmonary vascular resistance (PVR) and cardiac index (CI) as well as clinical outcomes.[6, 8–10] In addition, reduction in inflammatory mediators after treatment indicated improvement in functional class and long-term survival.[11]

Tumor necrosis factor receptor-associated factor (TRAF)-interacting protein with a forkhead-associated (FHA) domain (TIFA), an adapter protein functions as a key signaling transducer and activates nuclear factor kappa B (NF-κB).[12] Once stimulated by the upstream circulating TNF-α, TIFA is phosphorylated at threonine residual nine and undergoes oligomerization via the intermolecular binding between the FHA domain and the phosphorylated threonine.[13] TIFA oligomerization subsequently activates NF-κB and upregulates the expression of downstream inflammatory cytokines.[13] Although NF-κB upon activation has been reported to initiate the inflammatory cascade in PAH patients,[14, 15] whether TIFA protein is involved in the pathogenesis of PAH is yet undetermined. In the present study, we aimed to examine and compare the expression of TIFA in peripheral blood mononuclear cells (PBMCs) from patients with PAH,

hypertensive subjects, and healthy controls. We also investigated the association between TIFA protein expression, plasma levels of IL-1β and TNF-α, and pulmonary arterial hemodynamics.

Results

Baseline characteristics

A total of 99 subjects were enrolled in this study, including 48 group 1 PAH patients (age 50.1 ± 13.1 years, 22.9% men), 25 hypertensive patients (age 54.1 ± 9.3 years, 68% men), and 26 normal controls (age 57.6 ± 10.4 years, 46.2% men). Among the PAH patients, 32 (66.7%) had idiopathic PAH and 16 (33.3%) had connective tissue disease-associated PAH (CTD-PAH). The baseline characteristics are shown in Table 1. In brief, the PAH patient group was dominated by women, had lower blood pressure, estimated glomerular filtration rate (eGFR), and tricuspid annular plane systolic excursion (TAPSE), and higher left ventricular ejection fraction (LVEF) and estimated right ventricular systolic pressure (eRVSP), while hypertensive subjects had higher body mass index and blood pressure. PAH patients had significantly higher expression of TIFA protein in PBMCs and plasma IL-1β and TNF-α than the other patients, although these factors were also substantially higher in hypertensive subjects than in healthy controls. The generalized linear model adjusting for age, gender, and mean blood pressure (MAP) further confirmed the substantial increase in TIFA protein expression and plasma levels of IL-1β and TNF-α in the order of healthy controls, hypertensive subjects, idiopathic PAH patients, and CTD-PAH patients (Fig. 1).

Table 1
Baseline characteristics of the study population

Characteristic	Normal (n = 26)	Hypertension (n = 25)	PAH (n = 48)	P
Age, years	57.6 ± 10.4	54.1 ± 9.3	50.1 ± 13.1	0.054
Men, n (%)	12 (46.2)	17 (68.0)	11 (22.9)	0.001
BMI, kg/m^2	24.1 ± 3.3	26.6 ± 4.3*	23.4 ± 4.5	0.011
SBP, mmHg	131.2 ± 16.5	150.3 ± 15.6*	115.9 ± 17.5*	< 0.001
DBP, mmHg	79.2 ± 12.7	96.1 ± 11.5*	68.9 ± 13.4*†	< 0.001
MAP, mmHg	98.0 ± 14.5	117.9 ± 12.8*	86.3 ± 15.1*†	< 0.001
6MWD, m	-	-	343.4 ± 104.0	-
Laboratory tests				
BUN, mg/dL	14.7 ± 4.3	13.7 ± 2.7	17.3 ± 11.9	0.251
Creatinine, mg/dL	0.8 ± 0.2	0.8 ± 0.2	0.9 ± 0.3	0.305
eGFR‡, ml/min/1.73 m^2	92.4 ± 19.1	96.7 ± 15.8	82.7 ± 23.2†	0.026
NT-proBNP, pg/ml	-	-	1541.1 ± 2530.0	-
Echocardiography				
LVEF, %	63.0 ± 7.4	62.7 ± 1.4	67.8 ± 8.2*	0.013
eRVSP, mmHg	27.6 ± 10.8	23.5 ± 9.0	78.1 ± 37.7*†	< 0.001
TAPSE, cm	2.5 ± 0.5	2.6 ± 0.3	2.0 ± 0.5*†	< 0.001
Right heart catheterization				
PAWP, mmHg	-	-	11.0 ± 2.7	-
sPAP, mmHg	-	-	78.2 ± 29.4	-
mPAP, mmHg	-	-	49.9 ± 21.0	-
RAP, mmHg	-	-	12.0 ± 7.1	-
PVR, Wood units	-	-	14.4 ± 8.6	-
Inflammatory biomarkers				
TIFA, relative intensity	1.2 ± 0.5	1.9 ± 0.4*	3.25 ± 1.1*†	< 0.001
IL-1β, pg/ml	91.6 ± 87.9	154.2 ± 73.5	341.8 ± 110.3*†	< 0.001

Characteristic	Normal (n = 26)	Hypertension (n = 25)	PAH (n = 48)	*P*
TNF-α, pg/ml	79.4 ± 51.5	119.9 ± 38.9*	211.2 ± 58.1*†	*< 0.001*

Post-hoc analysis by Bonferroni test: * P < 0.05, vs. normal; † P < 0.05, vs. hypertension.

‡ eGFR was calculated from the Modification of Diet in Renal Disease equation for Asian.

6MWD = 6-minute walk distance; BMI = body mass index; BUN = blood urea nitrogen; DBP = diastolic blood pressure; eGFR = estimated glomerular filtration rate; eRVSP = estimated right ventricular systolic pressure; IL-1β = interleukin-1β; LVEF = left ventricular ejection fraction; mPAP = mean pulmonary artery pressure; MAP = mean arterial pressure; NT-proBNP = N-terminal pro-B type natriuretic peptide; PAH = pulmonary arterial hypertension; PAWP = pulmonary artery wedge pressure; PVR = pulmonary vascular resistance; RAP = right atrial pressure; SBP = systolic blood pressure; sPAP = systolic pulmonary artery pressure; TAPSE = tricuspid annular plane systolic excursion; TIFA = tumor necrosis factor-α receptor-associated factor-interacting protein with a forkhead-associated domain; TNF-α = tumor necrosis factor-α.

Association between TIFA protein expression, pro-inflammatory cytokines, and pulmonary arterial hemodynamics

The associations between TIFA protein expression in PBMCs and baseline characteristics are shown in Table 2. TIFA protein expression was positively associated with eRVSP (r = 0.45; *P* < 0.001), IL-1β (r = 0.94; *P* < 0.001), and TNF-α (r = 0.93; *P* < 0.001). In patients with PAH and invasive hemodynamics measurements, TIFA positively correlated with systolic pulmonary artery pressure (sPAP; r = 0.48; *P* = 0.001), mean pulmonary artery pressure (mPAP; r = 0.41; *P* = 0.006), and PVR (r = 0.41; *P* = 0.007), while in subjects without PAH, TIFA protein expression was positively associated with MAP (r = 0.449; *P* = 0.002).

Table 2
Correlations of TIFA with baseline characteristics and pulmonary arterial hemodynamics by using linear regression analysis

	r*	P
Total study population (n = 99)		
Age, years	-0.137	0.176
BMI, kg/m^2	-0.088	0.398
eGFR, ml/min/1.73 m^2	-0.118	0.299
LVEF, %	0.160	0.139
eRVSP, mmHg	0.450	< 0.001
IL-1β, pg/ml	0.938	< 0.001
TNF-α, pg/ml	0.934	< 0.001
Subjects with pulmonary arterial hypertension (n = 48)		
sPAP, mmHg	0.475	0.001
mPAP, mmHg	0.413	0.006
CI, L/min/m^2	-0.097	0.547
PVR, Wood unit	0.412	0.007
NT-proBNP, pg/ml	-0.084	0.575
6MWD, m	-0.244	0.114
Subjects without pulmonary arterial hypertension (n = 51)		
MAP, mmHg	0.449	0.002

* r: Pearson's correlation coefficient.

6MWD = 6-minute walk distance; BMI = body mass index; CI = cardiac index; eGFR = estimated glomerular filtration rate; eRVSP = estimated right ventricular systolic pressure; IL-1β = interleukin-1β; LVEF = left ventricular ejection fraction; MAP = mean blood pressure; mPAP = mean pulmonary artery pressure; NT-proBNP = N-terminal pro-B type natriuretic peptide; PVR = pulmonary vascular resistance; sPAP = systolic pulmonary artery pressure; TIFA = tumor necrosis factor-α receptor-associated factor-interacting protein with a forkhead-associated domain; TNF-α = tumor necrosis factor-α.

Diagnostic probability of PAH

TIFA protein expression in PBMCs, plasma IL-1β, and TNF-α all correlated with the presence of PAH (Table 3). After adjusting for age in the multivariate logistic regression analysis, TIFA, IL-1β, and TNF-α

remained as predictive markers of PAH in the study population (Table 3). The receiver operating characteristic (ROC) curve analysis revealed the area under curve of TIFA to be 0.95 (95% confidence interval: 0.89–0.98) for the prediction of PAH, suggesting that TIFA outperformed eRVSP (0.88, 0.80–0.94). With the use of TIFA (cutoff value, relative ratio of 2.1) to predict PAH diagnosis, the sensitivity was 100% (95% confidence interval, 92.6–100) and specificity was 90.2% (95% confidence interval, 78.6–96.7) (Fig. 2).

Table 3
Logistic regression analysis for the predictors of pulmonary arterial hypertension in the study population (n = 99)

Biomarkers	Unadjusted OR (95% CI) *	P	Adjusted OR (95% CI) *†	R^2 ‡	P
TIFA (1SD = 1.21)	1.722 (1.349–2.197)	< 0.001	1.722 (1.372–2.163)	0.812	< 0.001
IL-1β (1SD = 147.67 pg/ml)	1.488 (1.271–1.742)	< 0.001	1.486 (1.274–1.733)	0.763	< 0.001
TNF-α (1SD = 77.71 pg/ml)	1.414 (1.235–1.620)	< 0.001	1.449 (1.255–1.674)	0.763	< 0.001

* Odds ratio (OR) and 95% confidence interval (CI) per-0.1 standard deviation (SD) were presented.

† Adjusted for age.

‡ R^2 denotes Nagelkerke pseudo R-squared value.

IL-1β = interleukin-1β; TIFA = tumor necrosis factor-α receptor-associated factor-interacting protein with a forkhead-associated domain; TNF-α = tumor necrosis factor-α.

Causal inference between TIFA protein, pro-inflammatory cytokines, and the presence of PAH

The *ex vivo* study showed that small-interfering RNA (siRNA)-based TIFA protein expression silencing in PBMCs obtained from hypertensive or PAH patients resulted in a significant reduction of IL-1β and TNF-α levels (Fig. 3A and 3B). To understand the potential causal-relationship between TIFA and PAH, we conducted causal-mediation analyses and demonstrated significant indirect and total effects between TIFA and PAH mediated by IL-1β or TNF-α. These results suggest that upregulated TIFA protein expression may contribute to the development of PAH via the activation of IL-1β (attributable proportion [AP], 80.4%) and TNF-α (AP, 56.6%) (Fig. 4).

Discussion

To the best of our knowledge, this study is the first to demonstrate TIFA protein overexpression in PBMCs of PAH patients and the significant association between TIFA protein expression and plasma levels of IL-1β and TNF-α. TIFA protein expression positively correlated with PVR, an index of PAH severity, and could facilitate PAH diagnosis along with echocardiography. Furthermore, hypertensive subjects had upregulated expression of TIFA, IL-1β, and TNF-α as compared with the healthy controls. These results suggest that subclinical inflammation not only underlies the development of PAH but also systemic hypertension. *Ex vivo* silencing of TIFA protein expression suppressed the secretion of IL-1β and TNF-α in PBMCs from patients with PAH or systemic hypertension. Causal-mediation analysis further suggested that the effect of TIFA protein overexpression on the development of PAH could be mediated through both IL-1β and TNF-α.

Inflammation is well known to play an important role in PAH pathogenesis. Previous studies revealed the presence of abundant inflammatory cells infiltrating the remodeled pulmonary arterioles and the contribution of elevated circulating cytokines to the underlying inflammation.[16, 17] Higher serum levels of inflammatory mediators were shown to correlate with worse hemodynamic indices,[10] and were more predictive of adverse clinical outcomes than the conventional hemodynamic parameters such as CI or mPAP.[6, 18] Although the established role of inflammation in PAH has introduced a novel therapeutic paradigm,[19] the detailed inflammatory pathways in PAH remain unclear. Studies have shown that NF-κB is involved in the pathogenesis of PAH.[20] In 12 patients with end-stage idiopathic PAH who underwent lung transplantation, NF-κB was activated in pulmonary inflammatory cells, endothelial cells, and smooth muscle cells.[14] In the present study, we demonstrated the role of TIFA protein, a transducer that sustains the positive feedback signaling in the TNF-α−NF-κB axis,[13, 20, 21] in the crosstalk between endothelial, smooth muscle, and immune cells following development of cardiovascular diseases in PAH.[22−24]

Given that the underlying autoimmune disease may confound TIFA protein expression level, we further stratified PAH patients based on their etiologies into idiopathic PAH and CTD-PAH. As expected, the levels of inflammatory factors were higher in the CTD-PAH subgroup and may potentially indicate worse outcomes than idiopathic PAH.[25] The differences in TIFA protein expression observed in our study indicate a spectrum of varying degrees of inflammation in different etiologies of PAH. The significantly higher expression of TIFA protein in idiopathic PAH also manifested the role of inflammation even in the absence of CTD.

Aside from the PAH group, we also observed higher expression of inflammatory biomarkers in hypertensive subjects than in healthy controls. Mirhafez *et al.* demonstrated IL-1α, interferon-γ, and IL-10 as independent predictors of higher SBP and presence of hypertension in a cross-sectional study involving 155 hypertensive patients and 148 healthy subjects.[26] In a meta-analysis of 142,640 participants, Jayedi *et al.* suggested circulating C-reactive protein (CRP) and IL-6 to be associated with the risk of developing hypertension.[27] Although the exact mechanism remains to be elucidated, evidence shows that oxidized lipids may trigger the formation of atherosclerotic plaques and induce cytokine production via NF-κB activation.[28] By altering endothelial function, chronically activated

inflammation appears to increase arterial stiffness and contribute to the development of hypertension. [29, 30] In line with the findings, our study shows that hypertensive subjects had significant upregulation of TIFA protein expression in PBMCs as well as higher plasma IL-1β and TNF-α levels. The results not only support the role of inflammation in hypertension but also point out TIFA protein as a sensitive biomarker, adjunctive to other inflammatory mediators, to surrogate the extent of vascular remodeling underlying systemic hypertension.

The present study has several limitations. First, we reported a significant association between TIFA and PAH from a cross-sectional evaluation in a relatively small sample-sized study. Larger-scale studies with longitudinal follow-up are warranted to investigate the change in TIFA under PAH-specific treatment and to determine if it is a reliable marker to reflect PAH disease activity. Second, most patients from PAH group were women, which was compatible with the disease prevalence. Although gender was adjusted in the multivariable analysis, gender-specific variation should be considered, especially in the inflammatory signaling pathways. Third, although the present study shows that TIFA is involved in the pathogenesis of PAH, TIFA may not be specific to PAH and could also be elevated in the presence of underlying autoimmune diseases. Future studies should gather data on the associations between TIFA and other inflammatory markers, such as CRP level, and determine whether CTD-PAH patients have higher expression of TIFA protein than CTD patients without PAH.

TIFA protein expression in PBMCs is markedly increased in patients with PAH and positively correlates with PAH severity. As TIFA acts as an imperative transducer that propagates inflammatory responses by activating NF-κB signaling pathways,[13, 21, 24, 31] the study demonstrates the association between the upstream TIFA protein and the downstream plasma IL-1β and TNF-α in PAH. The findings of the present *in vitro* study may be considered as a promising aspect for further investigation in common animal models of PAH. In addition, the increased expression of TIFA protein in hypertensive subjects also indicates TIFA as a potentially sensitive marker of subclinical inflammation underlying the pathogenesis of PAH as well as hypertension. It is worth exploring the mechanisms of how TIFA initiates the progression of PAH and hypertension and the feasibility of TIFA as a novel therapeutic target in future studies.

Methods

Study participants

Patients aged > 18 years who were newly diagnosed with group 1 PAH as per the WHO classification, yet received any PAH-specific medication, were enrolled in this study from August 2016 to June 2018. The diagnosis of PAH was made according to practical guidelines.[32] Patients with either idiopathic PAH or CTD-PAH were further confirmed and included in the final analysis. In addition, subjects referred for the survey of hypertension were enrolled as controls. All the controls were subjected to 24-hour blood pressure recording (WatchBP O3, Microlife). Following the criteria of ambulatory blood pressure ≥ 130/80 mmHg of the 24-hour average, ≥ 135/85 mmHg of the daytime average, or ≥ 120/70 mmHg of

the nighttime average, participants were further classified as hypertensive subjects or healthy controls. This study was approved by the institutional review board at Taipei Veterans General Hospital, Taipei, Taiwan (IRB 2016-01-012AC), and was performed in accordance with relevant guidelines and regulations. Informed consent was obtained from all participants and/or their legal guardians.

Demography and clinical examinations

ll participants were analyzed for demographic measures, including body weight and height, blood pressure, and echocardiographic studies. Systolic and diastolic blood pressure (SBP and DBP) were recorded, and MAP was calculated as the sum of 1/3 SBP + 2/3 DBP. LVEF, eRVSP, and TAPSE were calculated according to the American Society of Echocardiography standard.[33] Fasting blood samples were collected for biochemical analysis, including blood urea nitrogen and creatinine. eGFR was calculated from the Modification of Diet in Renal Disease equation for Asians.[34]

For PAH patients, 6-minute walk distance (6MWD) and N-terminal pro-B type natriuretic peptide (NT-proBNP) levels were measured. Right heart catheterization was performed to obtain pulmonary hemodynamics, including pulmonary artery wedge pressure (PAWP), sPAP, mPAP, CI, and PVR.

Isolation of PBMCs, cell culture, and silencing of TIFA protein expression

A 15-mL whole blood sample was obtained from each participant, and PBMCs and plasma were isolated by density gradient centrifugation using Ficoll-Paque Plus (GE Healthcare, Piscataway, NJ, USA) as previously described.[21, 24] PBMCs were then maintained in Roswell Park Memorial Institute (RPMI)-1640 medium (Invitrogen) supplemented with 10% decomplemented fetal bovine serum (FBS; Gibco), 200 mmol/L L-glutamine (Gibco), 100 U/mL penicillin (Gibco), and 100 mg/mL streptomycin (Gibco) in a humidified atmosphere at 37 °C with 5% CO_2. For siRNA-based gene silencing, a total of 10^6 PBMCs were transfected with 50 pmol of double-stranded siRNA oligomers corresponding to the sequence 5′-UCA GGA CAA ACA GGU UUC CCG AGU U-3′ to target TIFA or control siRNA (synthesized by GenScript) supplemented with 15 μL of Lipofectamine RNAiMAX (Invitrogen) in the presence of Opti-MEM (Invitrogen). After 6 h from primary transfection, cells were incubated in regular medium for 24 h, and secondary siRNA transfection was performed using the same protocol. Cells and the conditioned media were collected after 72 h of incubation.

Estimations of the TIFA protein expression

To estimate TIFA protein expression in PBMCs, western blot analysis was performed following the previously established method.[21, 24] Briefly, patient PBMCs were washed with ice-cold phosphate-buffered saline (PBS), lysed in radioimmunoprecipitation assay (RIPA) lysis buffer (50 mM Tris pH 7.4, 150 mM sodium chloride [NaCl], 1% NP-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate [SDS]) supplemented with a protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (Sigma). After five repeated freeze-thaw cycles, the cell extracts were cleared by centrifugation at 4 °C. Cell extracts were quantified using the Bradford assay, and equal amounts of soluble proteins were mixed

with SDS sample buffer, boiled, separated by SDS-polyacrylamide gel electrophoresis (PAGE), and blotted onto polyvinylidene fluoride (PVDF) membranes (Millipore). Membranes were then blocked for 1 h with 5% dry milk in PBST (PBS supplemented with 0.1% Tween-20) buffer and incubated in a primary antibody diluted in PBST containing 1% bovine serum albumin (Sigma) for overnight at 4 °C. For detection of TIFA, a homemade anti-TIFA monoclonal antibody was used as previously described.[21] After three washes with PBST, membranes were incubated with a horseradish peroxidase (HRP)-conjugated anti-mouse IgG. Membranes were washed five times with PBST, and the blotted protein bands were revealed using an enhanced chemiluminescence (ECL) system (Millipore). The results of immunoblots were quantified and normalized to corresponding β-actin (Abcam) levels, and relative intensities normalized to normal counterparts were analyzed.

Measurement of pro-inflammatory cytokines

To assess the levels of cytokines in the plasma or conditioned media of cultured PBMCs, enzyme-linked immunosorbent assay (ELISA) test kits for IL-1β and TNF-α (R&D Systems) were used.[21] The absorbance of triplicate samples was read by SpectraMax Paradigm Plate Reader (Molecular Devices).

Statistical analysis

The baseline characteristics were reported as mean ± standard deviation for continuous variables and percentages for categorical variables. One-way analysis of variance (ANOVA) was performed to evaluate differences in baseline characteristics between normal subjects, hypertensive patients, and PAH patients. Post-hoc analysis with Bonferroni test was used for between-group comparisons. Linear regression analysis was employed to evaluate the correlation between TIFA protein expression and continuous variables, including IL-1β and TNF-α. A generalized linear model was used to calculate the estimated mean ± standard error of TIFA, IL-1β, and TNF-α in different groups after accounting for age, gender, and MBP. Logistic regression analysis was conducted after standardization and adjusting for age for TIFA, IL-1β, and TNF-α to clarify their role in the prediction of PAH. ROC curve analysis was used to derive the cut-off value of TIFA for the diagnosis of PAH, and the diagnostic powers of TIFA and echocardiographic measures were compared. Mediation analysis was performed to examine the causal–mediation relationship among TIFA, IL-1β, TNF-α, and PAH. Direct and indirect effects and confidence intervals were estimated by bootstrapping with 2,000 resamples. A two-tailed P value < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 22.0 (IBM, Chicago, IL, USA) and SAS 9.4 (IBM Inc., Cary, NC, USA).

Declarations

Data Availability

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgements

Author Contributions

M.D. Tsai and S.H. Sung conceived the present idea. H.C. Chang, T.Y. Wei, and P.Y. Wu acquired and performed the data analysis. W.C. Yu and S.H. Sung supervised the statistical analysis. M.D. Tsai, C.H. Chen, and S.H. Sung contributed to the interpretation of the results and revision of the manuscript. H.C. Chang and T.Y. Wei drafted the manuscript. C.H. Chen and S.H. Sung revised the manuscript. All authors reviewed and approved the final version of the manuscript.

Competing Interests

References

1. D'Alonzo, G. E. *et al.* Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. *Ann Intern Med.* **115**, 343-349 (1991).
2. Benza, R. L. *et al.* An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. *Chest.* **142**, 448-456 (2012).
3. McLaughlin, V. V., Shah, S. J., Souza, R. & Humbert, M. Management of pulmonary arterial hypertension. *J Am Coll Cardiol.* **65**, 1976-1997 (2015).
4. Groth, A. *et al.* Inflammatory cytokines in pulmonary hypertension. *Respir Res.* **15**, 47 (2014).
5. Price, L. C. *et al.* Inflammation in pulmonary arterial hypertension. *Chest.* **141**, 210-221 (2012).
6. Soon, E. *et al.* Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. *Circulation.* **122**, 920-927 (2010).
7. Humbert, M. *et al.* Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. *Am J Respir Crit Care Med.* **151**, 1628-1631 (1995).
8. Cracowski, J. L. *et al.* Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. *Eur Respir J.* **43**, 915-917 (2014).
9. Selimovic, N. *et al.* Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. *Eur Respir J.* **34**, 662-668 (2009).
10. Joshi, A. A. *et al.* Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension. *Pulm Circ.* **8**, 2045894018794051 (2018).
11. Hsu, C. H., Roan, J. N., Chen, J. H. & Lam, C. F. Functional Improvement and Regression of Medial Hypertrophy in the Remodeled Pulmonary Artery after Correction of Systemic Left-to-Right Shunt. *Sci Rep.* **6**, 37684 (2016).

12. Takatsuna, H. *et al.* Identification of TIFA as an adapter protein that links tumor necrosis factor receptor-associated factor 6 (TRAF6) to interleukin-1 (IL-1) receptor-associated kinase-1 (IRAK-1) in IL-1 receptor signaling. *J Biol Chem.* **278**, 12144-12150 (2003).

13. Huang, C. C. *et al.* Intermolecular binding between TIFA-FHA and TIFA-pT mediates tumor necrosis factor alpha stimulation and NF-kappaB activation. *Mol Cell Biol.* **32**, 2664-2673 (2012).

14. Price, L. C. *et al.* Nuclear factor kappa-B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension. *PLoS One.* **8**, e75415 (2013).

15. Hosokawa, S. *et al.* Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354. *Cardiovasc Res.* **99**, 35-43 (2013).

16. Tuder, R. M., Groves, B., Badesch, D. B. & Voelkel, N. F. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. *Am J Pathol.* **144**, 275-285 (1994).

17. Savai, R. *et al.* Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med.* **186**, 897-908 (2012).

18. Eddahibi, S. *et al.* Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. *Proc Am Thorac Soc.* **3**, 475-476 (2006).

19. Hernandez-Sanchez, J. *et al.* Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. *Pulm Circ.* **8**, 2045893217735820 (2018).

20. Wang, Q. *et al.* Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-alpha antagonists via the suppression of TNF-alpha expression and NF-kappaB pathway in rats. *Vascul Pharmacol.* **58**, 71-77 (2013).

21. Wei, T. W. *et al.* Aurora A and NF-kappaB Survival Pathway Drive Chemoresistance in Acute Myeloid Leukemia via the TRAF-Interacting Protein TIFA. *Cancer Res.* **77**, 494-508 (2017).

22. Buckley, L. F. & Abbate, A. Interleukin-1 blockade in cardiovascular diseases: a clinical update. *Eur Heart J.* **39**, 2063-2069 (2018).

23. Azzawi, M. & Hasleton, P. Tumour necrosis factor alpha and the cardiovascular system: its role in cardiac allograft rejection and heart disease. *Cardiovasc Res.* **43**, 850-859 (1999).

24. Lin, T. Y. *et al.* TIFA as a crucial mediator for NLRP3 inflammasome. *Proc Natl Acad Sci U S A.* **113**, 15078-15083 (2016).

25. Thenappan, T. *et al.* Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. *Eur Respir J.* **35**, 1079-1087 (2010).

26. Mirhafez, S. R. *et al.* An imbalance in serum concentrations of inflammatory and anti-inflammatory cytokines in hypertension. *J Am Soc Hypertens.* **8**, 614-623 (2014).

27. Jayedi, A. *et al.* Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies. *Heart.* doi:10.1136/heartjnl-2018-314216 (2019).

28. Libby, P. Inflammation in atherosclerosis. *Nature.* **420**, 868-874 (2002).

29. Renna, N. F., de Las Heras, N. & Miatello, R. M. Pathophysiology of vascular remodeling in hypertension. *Int J Hypertens.* **2013**, 808353 (2013).

30. Tomiyama, H. *et al.* The Contribution of Inflammation to the Development of Hypertension Mediated by Increased Arterial Stiffness. *J Am Heart Assoc.* **6**, doi:10.1161/JAHA.117.005729 (2017).

31. Ea, C. K., Sun, L., Inoue, J. & Chen, Z. J. TIFA activates IkappaB kinase (IKK) by promoting oligomerization and ubiquitination of TRAF6. *Proc Natl Acad Sci U S A.* **101**, 15318-15323 (2004).

32. Galie, N. *et al.* 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J.* **37**, 67-119 (2016).

33. Rudski, L. G. *et al.* Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr.* **23**, 685-713 (2010).

34. Ma, Y. C. *et al.* Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. *J Am Soc Nephrol.* **17**, 2937-2944 (2006).

Figures

Figure 1

Generalized linear models of TIFA protein expression in PBMCs and plasma levels of IL-1β and TNF-α after adjusting for age, gender, and mean blood pressure in normal controls, hypertensive (HTN) subjects, patients with idiopathic pulmonary arterial hypertension (iPAH) (n=32), and patients with connective tissue disease-associated PAH (CTD-PAH) (n=16). * P< 0.001; † P< 0.01; All values are expressed as mean ± standard error. IL-1β= interleukin-1β; TIFA= tumor necrosis factor-α receptor-associated factor-interacting protein with a forkhead-associated domain; TNF-α= tumor necrosis factor-α.

	Sensitivity (95% CI)	Specificity (95% CI)
TIFA> 2.1	100% (92.6-100)	90.2% (78.6-96.7)
eRVSP> 40	87.2% (74.3-95.2)	93.8% (82.8-98.7)

Figure 2

Diagnostic performance of a TIFA value of > 2.1 and an echocardiographic estimation of right ventricular systolic pressure (eRVSP) of > 40 mmHg for pulmonary arterial hypertension (PAH) in the study population. Solid circles = PAH; empty circles = non-PAH. CI= confidence interval.

Figure 3

Silencing of TIFA protein expression leads to decreased secretions of (A) TNF-α and (B) IL-1β in cultured peripheral blood mononuclear cells from patients with pulmonary arterial hypertension (PAH) and hypertension (HTN). * P< 0.05; ** P< 0.01; *** P< 0.001. IL-1β= interleukin-1β; siCon= control siRNA; siTIFA= TIFA siRNA; TIFA= tumor necrosis factor-α receptor-associated factor-interacting protein with a forkhead-associated domain; TNF-α= tumor necrosis factor-α.